Literature DB >> 28879191

Patient-Reported Outcomes in Onychomycosis: A Review of Psychometrically Evaluated Instruments in Assessing Treatment Effectiveness.

Jenny Wang1, Lauren E Wiznia2, Evan A Rieder2.   

Abstract

PURPOSE: Onychomycosis is the most common nail disorder and causes morbidity and impaired quality of life (QOL). Patient-reported outcomes (PRO) are patients' assessment of their health status or treatment response. PROs help assess what is most bothersome to patients to identify targets for intervention. We sought to review the PRO instruments currently used to assess QOL and treatment response in onychomycosis patients. PROCEDURES: A systematic review was performed by searching PubMed, Embase, CINAHL, and PsycINFO databases through December 31, 2016, to identify all English language literature on onychomycosis, PRO, and QOL.
RESULTS: Currently, 5 validated PRO instruments exist specifically for onychomycosis. Oral therapies were most extensively studied using PRO instruments. QOL data generally correlated with clinical change, although patients sometimes reported improvement without any clinically significant nail clearance. The only psychometrically validated PRO instrument used to evaluate treatment response is the OnyCOE-t™.
CONCLUSIONS: Clinicians may underestimate the impact of onychomycosis on patients. With recent initiatives from health-care management organizations to improve patient experience and the recent approval of expensive and nonsuperior topical antifungal medications, PROs will be increasingly important in onychomycosis to assess patient priorities and optimize treatment. Future research should evaluate these instruments in special populations and fingernail disease.

Entities:  

Keywords:  Nail diseases; Nails; Onychomycosis; Patient-reported outcomes; Psychometrics; Quality of life; Questionnaires

Year:  2017        PMID: 28879191      PMCID: PMC5582516          DOI: 10.1159/000469666

Source DB:  PubMed          Journal:  Skin Appendage Disord        ISSN: 2296-9160


  36 in total

Review 1.  Health-related quality-of-life assessment in dermatologic practice: relevance and application.

Authors:  O D van Cranenburgh; C A C Prinsen; M A G Sprangers; Ph I Spuls; J de Korte
Journal:  Dermatol Clin       Date:  2011-12-20       Impact factor: 3.478

2.  A Novel Treatment for Onychomycosis in People Living With HIV Infection: Vicks VapoRub™ is Effective and Safe.

Authors:  Mariea Snell; Michael Klebert; Nur F Önen; Sara Hubert
Journal:  J Assoc Nurses AIDS Care       Date:  2015-10-30       Impact factor: 1.354

3.  Effect of onychomycosis on quality of life.

Authors:  L A Drake; R K Scher; E B Smith; G A Faich; S L Smith; J J Hong; M J Stiller
Journal:  J Am Acad Dermatol       Date:  1998-05       Impact factor: 11.527

4.  Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients.

Authors:  A K Gupta; H C Jain; C W Lynde; P Macdonald; E A Cooper; R C Summerbell
Journal:  J Am Acad Dermatol       Date:  2000-08       Impact factor: 11.527

5.  Evaluation of quality of life in patients with toenail onychomycosis by Polish version of an international onychomycosis-specific questionnaire.

Authors:  J C Szepietowski; A Reich; P Pacan; E Garlowska; E Baran
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-04       Impact factor: 6.166

6.  Onychomycosis is more than a cosmetic problem.

Authors:  R K Scher
Journal:  Br J Dermatol       Date:  1994-04       Impact factor: 9.302

7.  Patient satisfaction with oral versus nonoral therapeutic approaches in onychomycosis.

Authors:  D M Stier; D Gause; W S Joseph; J R Schein; J M Broering; K L Warolin; J J Doyle
Journal:  J Am Podiatr Med Assoc       Date:  2001 Nov-Dec

8.  Onychomycosis: a significant medical disorder.

Authors:  R K Scher
Journal:  J Am Acad Dermatol       Date:  1996-09       Impact factor: 11.527

9.  Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial.

Authors:  D Scot Malay; Sang Yi; Pamela Borowsky; Michael S Downey; Alan J Mlodzienski
Journal:  J Foot Ankle Surg       Date:  2009 May-Jun       Impact factor: 1.286

10.  The OnyCOE-t questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis.

Authors:  Lori P Potter; Susan D Mathias; Monika Raut; Farid Kianifard; Amir Tavakkol
Journal:  Health Qual Life Outcomes       Date:  2006-08-15       Impact factor: 3.186

View more
  2 in total

1.  Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: A multicenter, single-arm study.

Authors:  Ken Iozumi; Masatoshi Abe; Yoshiko Ito; Takashi Uesugi; Takashi Onoduka; Ichiro Kato; Fumihiro Kato; Kazuo Kodama; Hidetoshi Takahashi; Osamu Takeda; Koki Tomizawa; Tomoko Nomiyama; Mizue Fujii; Jun Mayama; Fumio Muramoto; Hidemi Yasuda; Kiyomitsu Yamanaka; Tomotaka Sato; Tsunao Oh-I; Hiroko Kasai; Ryoji Tsuboi; Naoko Hattori; Ryuji Maruyama; Tokuya Omi; Harunari Shimoyama; Yoshihiro Sei; Ichiro Nakasu; Shuhei Nishimoto; Yasuki Hata; Takashi Mochizuki; Masao Fukuzawa; Mariko Seishima; Kazumitsu Sugiura; Ichiro Katayama; Osamu Yamamoto; Masahisa Shindo; Hiroe Kiryu; Masahiro Kusuhara; Motoi Takenaka; Shinichi Watanabe
Journal:  J Dermatol       Date:  2019-06-17       Impact factor: 4.005

2.  Translation and Cross-Cultural Adaptation of Quality of Life Scale in Patients with Onychomycosis.

Authors:  Vasco Silva-Neves; Ana Caramelo; Paulo Alves; Carla Pais-Vieira; Alexandra Palmer Minton; Ana María Rodríguez-Leboeuf; Miguel Pais-Vieira
Journal:  Int J Environ Res Public Health       Date:  2021-05-28       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.